These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24658009)

  • 1. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
    Link PA; Zhang W; Odunsi K; Karpf AR
    Cancer Immun; 2013; 13():6. PubMed ID: 23390377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
    Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
    Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
    Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
    Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
    Nguyen P; Cui H; Bisht KS; Sun L; Patel K; Lee RS; Kugoh H; Oshimura M; Feinberg AP; Gius D
    Cancer Res; 2008 Jul; 68(14):5546-51. PubMed ID: 18632606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BORIS in human cancers -- a review.
    Martin-Kleiner I
    Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
    Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
    Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes.
    Hore TA; Deakin JE; Marshall Graves JA
    PLoS Genet; 2008 Aug; 4(8):e1000169. PubMed ID: 18769711
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
    Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.
    Hoffmann MJ; Müller M; Engers R; Schulz WA
    Biochem Pharmacol; 2006 Nov; 72(11):1577-88. PubMed ID: 16854382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Diverging Routes of BORIS and CTCF: An Interactomic and Phylogenomic Analysis.
    Jabbari K; Heger P; Sharma R; Wiehe T
    Life (Basel); 2018 Jan; 8(1):. PubMed ID: 29385718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structural complexity of the human BORIS gene in gametogenesis and cancer.
    Pugacheva EM; Suzuki T; Pack SD; Kosaka-Suzuki N; Yoon J; Vostrov AA; Barsov E; Strunnikov AV; Morse HC; Loukinov D; Lobanenkov V
    PLoS One; 2010 Nov; 5(11):e13872. PubMed ID: 21079786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
    Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
    PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
    Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
    Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovering a binary CTCF code with a little help from BORIS.
    Lobanenkov VV; Zentner GE
    Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
    Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
    Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma.
    He J; Huang Y; Liu Z; Zhao R; Liu Q; Wei L; Yu X; Li B; Qin Y
    Gene; 2017 Sep; 629():29-34. PubMed ID: 28764977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CTCFL/BORIS for the immunotherapy of cancer.
    Loukinov D
    Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.